Submission to first decision (The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor)
Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date.
3 weeks
Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) 6 weeks
Submission to final decision (The average time from manuscript submission to the final editorial decision) 16 weeks
Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) 24 weeks

ACTA Pharmaceutica Sciencia 2026 , Vol 64 , Num 4
Differential apoptosis-associated responses of neurons and glial cells to cisplatin in primary cortical cultures
Neşe AYŞİT 1-2-3 Ayça ÖNAL 1-2-3 Esra ALTINTAŞ 1-2-3 Arda KEBAPÇI 1-2-3
1 İstanbul Medipol University, Regenerative and Restorative Medicine Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), İstanbul, Türkiye
2 İstanbul Medipol University, Graduate School of Health Sciences, Istanbul, Türkiye
3 İstanbul Medipol University, School of Medicine, Department of Medical Biology, Istanbul, Türkiye
DOI : 10.23893/1307-2080.APS64030 Viewed : 628 - Downloaded : 280 Cisplatin is a platinum-based chemotherapeutic agent widely used to treat solid tumors; however, its clinical use is limited by severe neurotoxicity. Although cisplatin shows limited blood–brain barrier permeability, accumulating evidence indicates that it induces apoptosis-associated neurotoxicity in the central nervous system. In this study, we investigated cell type–specific apoptosis-associated responses of primary cortical neurons and glial cells to cisplatin. Cytotoxicity was evaluated in EMT6 murine mammary carcinoma cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and the half-maximal inhibitory concentration (IC₅₀) was determined. This concentration was then applied to primary cortical cultures derived from postnatal day 0 Balb/C mice. Apoptosis-associated responses were assessed by Western blot analysis of BCL-2 expression and immunofluorescence staining of caspase-3. Cisplatin significantly reduced BCL-2 protein levels in primary cortical cultures (p<0.01). Immunofluorescence analysis further revealed a significant increase in caspase-3–positive neurons following cisplatin exposure (p<0.01), whereas no significant change was observed in GFAP-positive glial cells (p>0.05). These findings demonstrate that cisplatin induces cell type–specific apoptosis-associated responses in primary cortical cultures, with neurons showing greater vulnerability than glial cells, highlighting the importance of evaluating cisplatin-induced neurotoxicity in the central nervous system. Keywords : cisplatin, neurotoxicity, apoptosis, caspase 3, cerebral cortex

Istanbul Medipol University